Who are Nanjing Leads Biolabs's main competitors?

Named competitors: Akeso (9926.HK), Innovent Biologics (1801.HK), Alphamab Oncology (9966.HK), RemeGen (9995.HK). The cockpit's measured peer set (industry) also includes Odyssey Therapeutics (ODTX), Inventiva (IVA.PA), Monte Rosa Therapeutics (GLUE), Jade Biosciences (JBIO), China Animal Husbandry Industry (600195.SS), Oxford BioMedica (OXB.L).

Is Nanjing Leads Biolabs expensive compared with its peers?

On ev / sales it trades at 26.5× against a peer median of 6.1×, 4th most expensive of 19 in its peer set.

How has Nanjing Leads Biolabs stock performed?

Over six months to 6 Nov 2026 the shares returned -53.8% against -10.9% for the median peer; over one year -38.0%.

← CockpitCompetitor Analysis › 9887.HK Nanjing Leads Biolabs Co., Ltd. Class HOpen in the cockpit ↗

Nanjing Leads Biolabs Co., Ltd. Class H9887.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Biotechnology

Nanjing-based Chinese biotech developing antibody and bispecific-antibody therapeutics for cancer and autoimmune disease.

Momentum laggard 6

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$927M

US dollars, full cap

Free float

63%

of shares outstanding

$/day

$5.80M

20-day average traded

Fwd P/E

n/m

no positive forecast

ROIC−WACC

n/a

WACC 12.3%

Hurdle

n/a

no reverse DCF

Next earnings

143 days

29 Mar 2027

Close · HKDHK$36.56

1D-4.2%

1W+1.6%

1M-26.3%

3M-43.1%

6M-53.8%

YTD-28.3%

1Y-38.0%

ATR %7.5%

52w lowhigh62.5% off high

What Nanjing Leads Biolabs does

Nanjing-based Chinese biotech developing antibody and bispecific-antibody therapeutics for cancer and autoimmune disease.

Has no marketed drug, so it is paid through licensing: partners hand over an upfront fee and later milestone payments as a drug passes trial stages, while the rest of its funding comes from selling shares. Its bispecific candidates, which bind two targets at once, are what partners are buying.

Products and services

Bispecific antibody pipeline
Oncology antibody candidates
Autoimmune disease pipeline

Customers

Global pharma licensing partners

Where it sits in the supply chain

Biopharmaceuticals
Antibody drug discovery
Out-licensing/co-development

What could go right

Licensing deal milestone payments

What could go wrong

Clinical-stage/no approved products
Funding/cash runway risk

Moat: narrow (IP / patents). Proprietary bispecific-antibody platform, but early-stage pipeline with unproven commercial products.

Headquarters: Nanjing, China · Employees: 244

Named competitors

Akeso 9926.HK
Innovent Biologics 1801.HK
Alphamab Oncology 9966.HK
RemeGen 9995.HK

Nanjing Leads Biolabs at a glance

Size Nanjing Leads Biolabs (9887.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $927M, the 611th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$36.56 on 6 Nov 2026.

Performance Over six months the shares fell 53.8%, against -10.9% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 2nd lowest of 20 in its peer set.

Growth The operating margin is -107.8% (peer median -24.8%).

Valuation It trades at 26.5× enterprise value to sales against a peer median of 6.1× (4th most expensive of 19).

Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).

Relative performance

Six months, rebased to 100: Nanjing Leads Biolabs against the median of its 20 peers (local-currency closes).

Nanjing Leads Biolabs financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	HK$235M	HK$192M	HK$0	HK$9.80M	HK$0
Revenue growth	—	—	-100%	—	—
Gross profit	n/a	n/a	-HK$28.2M	-HK$20.1M	-HK$20.2M
EBITDA	-HK$229M	-HK$188M	-HK$268M	-HK$264M	-HK$223M
Net income	-HK$302M	-HK$229M	-HK$327M	-HK$400M	-HK$327M
Free cash flow	n/a	-HK$184M	-HK$138M	-HK$233M	-HK$84.7M
Capital expenditure	n/a	HK$11.3M	HK$3.23M	HK$13.0M	HK$33.9M
Total debt	n/a	HK$312M	HK$284M	HK$1.51B	HK$1.35B

Quarterly statements and history in the cockpit →

Nanjing Leads Biolabs competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Nanjing Leads Biolabs is the large dot.

Nanjing Leads Biolabs competitors and peer comparison

Head to head with its named competitors (9887.HK vs 9926.HK vs 1801.HK vs 9966.HK)
Company	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g
Nanjing Leads Biolabs 9887.HK	$927M	-54%	n/a	-108%	26.5×	n/a
Akeso 9926.HK	$10.2B	-38%	+42%	-25%	19.5×	n/a
Innovent Biologics 1801.HK	$19.2B	-5%	+43%	17%	7.4×	11.7%
Alphamab Oncology 9966.HK	$777M	-39%	-32%	-38%	8.2×	n/a
RemeGen 9995.HK	$6.92B	-31%	+293%	61%	5.1×	-4.8%

How Nanjing Leads Biolabs compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Nanjing Leads Biolabs against its 20 peers (data as of 6 Nov 2026)
Measure	9887.HK	Peer median	Rank in peer set
1-month return	-26.3%	-4.6%	3rd lowest of 21
6-month return	-53.8%	-10.9%	2nd lowest of 20
Distance from 52-week high	-62.5%	-40.0%	2nd lowest of 21
Operating margin	-107.8%	-24.8%	7th lowest of 19
EV / Sales	26.5×	6.1×	4th most expensive of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g	Delivered g
Nanjing Leads Biolabs 9887.HK	Hong Kong	$927M	-54%	n/a	-108%	26.5×	n/a	n/a
Odyssey Therapeutics ODTX	United States	$924M	n/a	-33%	-5,415%	208.9×	n/a	n/a
Inventiva IVA.PA	France	$912M	-29%	-100%	-307,063%	14,560.9×	n/a	n/a
Monte Rosa Therapeutics GLUE	United States	$902M	-45%	-84%	-633%	11.1×	n/a	n/a
Jade Biosciences JBIO	United States	$958M	-42%	n/a	n/a	n/a	n/a	n/a
China Animal Husbandry Industry 600195.SS	China	$960M	-17%	+1%	2%	1.4×	6.6%	+4.4%
Oxford BioMedica OXB.L	United Kingdom	$892M	-14%	+16%	-18%	4.3×	n/a	n/a
Alto Neuroscience ANRO	United States	$987M	+4%	n/a	n/a	n/a	n/a	n/a
GNI 2160.T	Japan	$866M	-29%	+10%	-24%	5.7×	n/a	n/a
MeiraGTx MGTX	United States	$864M	-8%	+948%	46%	2.1×	-9.9%	+39.2%
Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZ	China	$995M	-11%	0%	22%	4.7×	11.1%	+2.3%
Syndax Pharmaceuticals SNDX	United States	$859M	-56%	+160%	-62%	3.5×	n/a	n/a
Changchun BCHT Biotechnology 688276.SS	China	$1.00B	-11%	+2%	-29%	10.0×	n/a	n/a
Peptidream 4587.T	Japan	$856M	-10%	+1%	-25%	6.6×	n/a	n/a
Innovita Biological Technology 688253.SS	China	$1.02B	-4%	-28%	11%	16.3×	42.9%	-16.6%
Prime Medicine PRME	United States	$843M	+45%	-18%	-4,825%	211.3×	n/a	n/a
Verastem VSTM	United States	$1.02B	+72%	+3,996%	-183%	11.1×	n/a	n/a
Wuhan Keqian Biology 688526.SS	China	$814M	-19%	-22%	20%	4.7×	8.8%	+2.4%
R&G PharmaStudies 301333.SZ	China	$803M	-12%	+21%	11%	3.9×	20.1%	+11.8%
Anhui Wanbang Pharmaceutical Technology 301520.SZ	China	$803M	+91%	-15%	-8%	17.9×	48.8%	+14.7%
Janux Therapeutics JANX	United States	$1.08B	+24%	+5,367%	-598%	5.3×	n/a	n/a

Questions

Who are Nanjing Leads Biolabs's main competitors?: Named competitors: Akeso (9926.HK), Innovent Biologics (1801.HK), Alphamab Oncology (9966.HK), RemeGen (9995.HK). The cockpit's measured peer set (industry) also includes Odyssey Therapeutics (ODTX), Inventiva (IVA.PA), Monte Rosa Therapeutics (GLUE), Jade Biosciences (JBIO), China Animal Husbandry Industry (600195.SS), Oxford BioMedica (OXB.L).
Is Nanjing Leads Biolabs expensive compared with its peers?: On ev / sales it trades at 26.5× against a peer median of 6.1×, 4th most expensive of 19 in its peer set.
How has Nanjing Leads Biolabs stock performed?: Over six months to 6 Nov 2026 the shares returned -53.8% against -10.9% for the median peer; over one year -38.0%.